The Kansas Interdisciplinary Center for PKD Research (Kansas PKD Center) was established to provide support for highly meritorious new research programs to explore the basic mechanisms causing polycystic kidney disease (PKD); to provide opportunities to bring new investigators into PKD research; and to foster opportunities for more interdisciplinary research in a dynamic, enriching, and interactive setting. The long term goal for the Kansas PKD Center is to find a treatment for PKD that will alleviate the suffering of patients and families affected by the disease. The central theme of the research projects in the Kansas PKD Center is """"""""cell proliferation in polycystic kidney disease."""""""" This theme was chosen because Center investigators have been able to identify the cell proliferation defect in PKD as one that involves a cyclic AMP- and calcium-dependent mechanism. The focus will be on using the mouse as a model organism, and on human PKD cyst cells. The Kansas PKD Center is comprised of eight components. The Administrative Core will provide administrative support for Center investigators. The Biomaterials Research Core will establish and maintain a repository of human and animal biological materials for PKD research including primary cultured cells and tissues, and DMA and RNA from ADPKD, ARPKD, and normal human kidney tissues. The Core will also establish and maintain immortalized cell lines from mice carrying unique PKD gene mutations and will provide technical assistance and training in cell culture methodology for all Center investigators. There will be four Biomedical Research Projects: Project 1, """"""""Calcium Regulation of cAMP-Dependent Proliferation,"""""""" Project 2, """"""""Polycystin-1 Mediated Calcium and cAMP Signaling,"""""""" Project 3, """"""""Role of Oxidant Stress in Progression of PKD,"""""""" and Project 4, """"""""Cux-1 and Cell Cycle Regulation in PKD.""""""""

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center (P50)
Project #
5P50DK057301-08
Application #
7127287
Study Section
Special Emphasis Panel (ZDK1-GRB-9 (O1))
Program Officer
Flessner, Michael Francis
Project Start
1999-09-30
Project End
2010-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
8
Fiscal Year
2006
Total Cost
$1,069,425
Indirect Cost
Name
University of Kansas
Department
Biochemistry
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Parnell, Stephen C; Magenheimer, Brenda S; Maser, Robin L et al. (2018) A mutation affecting polycystin-1 mediated heterotrimeric G-protein signaling causes PKD. Hum Mol Genet 27:3313-3324
Paul, Binu M; Vanden Heuvel, Gregory B (2014) Kidney: polycystic kidney disease. Wiley Interdiscip Rev Dev Biol 3:465-87
Zhou, Xia; Fan, Lucy X; Li, Keguo et al. (2014) SIRT2 regulates ciliogenesis and contributes to abnormal centrosome amplification caused by loss of polycystin-1. Hum Mol Genet 23:1644-55
Swenson-Fields, Katherine I; Vivian, Carolyn J; Salah, Sally M et al. (2013) Macrophages promote polycystic kidney disease progression. Kidney Int 83:855-64
Qiu, Ni; Xiao, Zhousheng; Cao, Li et al. (2012) Conditional mesenchymal disruption of pkd1 results in osteopenia and polycystic kidney disease. PLoS One 7:e46038
Fan, Lucy X; Li, Xinjian; Magenheimer, Brenda et al. (2012) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81:76-85
Parnell, Stephen C; Puri, Sanjeev; Wallace, Darren P et al. (2012) Protein phosphatase-1ýý interacts with and dephosphorylates polycystin-1. PLoS One 7:e36798
Karihaloo, Anil; Koraishy, Farrukh; Huen, Sarah C et al. (2011) Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22:1809-14
Nims, Nancy M; Vassmer, Dianne; Maser, Robin L (2011) Effect of PKD1 gene missense mutations on polycystin-1 membrane topogenesis. Biochemistry 50:349-55
Reif, Gail A; Yamaguchi, Tamio; Nivens, Emily et al. (2011) Tolvaptan inhibits ERK-dependent cell proliferation, Clýýý secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301:F1005-13

Showing the most recent 10 out of 62 publications